Durvalumab + SoC chemotherapy
D910LC00001
Phase 3 small_molecule completed
Quick answer
Durvalumab + SoC chemotherapy for Carcinoma, Non-Small-Cell Lung is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Carcinoma, Non-Small-Cell Lung
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed